Evidence network for deaths_(OS)

1IMpassion-031 (all population), 20201ALEXANDRA/IMpassion-030, 20241KEYNOTE-522, 20201OlympiA (BIG 6-13, NSABP B-55), 0nab-paclitaxelStandard of Care (SoC)pegylated liposomal doxorubicin and cyclophosphamidepaclitaxel followed by doxorubicin plus cyclophosphamideplacebocarboplatin plus nab-paclitaxelpaclitaxelcarboplatindurvalumab alonepembrolizumab plus SoCatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelolaparibatezolizumab plus carboplatin plus nab-paclitaxelatezolizumab plus carboplatin plus paclitaxeldirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelStandard of Care (SoC)pegylated liposomal doxorubicin and cyclophosphamidepaclitaxel followed by doxorubicin plus cyclophosphamideplacebocarboplatin plus nab-paclitaxelpaclitaxelcarboplatindurvalumab alonepembrolizumab plus SoCatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelolaparibatezolizumab plus carboplatin plus nab-paclitaxelatezolizumab plus carboplatin plus paclitaxel
nab-paclitaxel---NANANANANANANANANANANANANANA
Standard of Care (SoC)NA---NANANANANANANANANANANANANA
pegylated liposomal doxorubicin and cyclophosphamideNANA---NANANANANANANANANANANANA
paclitaxel followed by doxorubicin plus cyclophosphamideNANANA---NANANANANANANANANANANA
placeboNANANANA---NANANANANANANANANANA
carboplatin plus nab-paclitaxelNANANANANA---NANANANANANANANANA
paclitaxelNANANANANANA---NANANANANANANANA
carboplatinNANANANANANANA---NANANANANANANA
durvalumab aloneNANANANANANANANA---NANANANANANA
pembrolizumab plus SoCNANANANANANANANANA---NANANANANA
atezolizumab plus nab-paclitaxelNANANANANANANANANANA---NANANANA
atezolizumab plus paclitaxelNANANANANANANANANANANA---NANANA
olaparibNANANANANANANANANANANANA---NANA
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANANANANANANA---NA
atezolizumab plus carboplatin plus paclitaxelNANANANANANANANANANANANANANA---

pathologies: 305 - treatments: 744 result logic